Clinical data from independent investigator-initiated studies using [⁶⁸Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary Aldosteronism First-in-human findings with ...
Clinical data from independent investigator-initiated studies using [68Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary AldosteronismFirst-in-human findings with [¹77Lu]Lu-Pentix ...
Phase 2 Trial in Multiple Myeloma Nears Key ReadoutPreparing for Expansion into Sickle Cell Disease and Acute Myeloid ...
Barcelona-based Nanoligent, a biotechnology company specialised in the development of targeted nanodrugs for cancer treatment, has secured €12M in a new ...
Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025Presented ...
Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development ...
TipRanks on MSN
Exicure announces near-term strategic priorities
Exicure’s (XCUR) ongoing Phase 2 study is a randomized, open-label, multicenter trial evaluating burixafor, a small molecule CXCR4 antagonist, in ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has filed its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback